Hypertension

Explains the effect of the COVID-19 pandemic on clinical research and provides suggestions for which studies should proceed, which should pivot to research on the pandemic, which should be paused, and which should stop.

Summarizes clinical trial evidence suggesting a possible link between angiotensin receptor blocker use and cancer, additional clinical evidence tending to refute a link, basic science evidence, and recent information about the problem of potentially cancer-causing impurities found in some angiotensin receptor blocker products.

We review the recent guidelines addressing the diagnosis and management of hypertension.

We provide insights into the effects of recent blood pressure medication recalls on patients, healthcare providers, and health systems.

Invited editorial comment on a new approach to evaluating whether patients are similar to those actually enrolled in a clinical trial, as opposed to the inclusion and exclusion criteria.

Editorial page describing our journal's strengthened ties with the British and Irish Hypertension Society.

Proposes a framework for thinking about pragmatic, one-size-fits-most treatment and highly personalized treatment of hypertension.

**Context:** Many antihypertensive medications modulate the renin-angiotensin-aldosterone system, possibly skewing the diagnosis and subtyping of primary aldosteronism (PA). Particularly, mineralocorticoid receptor antagonists (MRA) might raise renin …

We explain the approach to out-of-office blood pressure monitoring in 2018.

This patient page explains the use of 24-hour ambulatory blood pressure monitoring.